Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Sales | 59,988 | 90,142 | 88,478 | 69,555 | 91,977 |
| Cost of Goods | 24,239 | 59,089 | 18,613 | 38,147 | 38,263 |
| Gross Profit | 35,749 | 31,053 | 69,865 | 31,408 | 53,714 |
| Operating Expenses | 94,083 | 204,961 | 129,603 | 126,446 | 109,882 |
| Operating Income | -58,095 | -173,819 | -59,125 | -94,891 | -55,905 |
| Interest Expense | 2,274 | 2,308 | 1,972 | -307 | 0 |
| Other Income | 410 | 376 | 350 | -1,651 | 43 |
| Pre-tax Income | -59,959 | -175,751 | -60,747 | -96,235 | -55,862 |
| Income Tax | N/A | N/A | N/A | -1,752 | -1,277 |
| Net Income Continuous | -59,959 | -175,751 | -60,747 | -94,483 | -54,585 |
| Net Income | $-59,959 | $-175,751 | $-60,747 | $-94,483 | $-54,585 |
| EPS Basic Total Ops | -0.42 | -1.28 | -0.47 | -0.79 | -0.46 |
| EPS Basic Continuous Ops | -0.42 | -1.28 | -0.47 | -0.79 | -0.46 |
| EPS Diluted Total Ops | -0.42 | -1.28 | -0.47 | -0.79 | -0.46 |
| EPS Diluted Continuous Ops | -0.42 | -1.28 | -0.47 | -0.79 | -0.46 |
| EBITDA(a) | $-51,504 | $-48,673 | $-49,500 | $-85,229 | $-46,281 |